Benzamide,5-(1-aziridinyl)-2,4-dinitro-
| Title | Journal |
|---|---|
| Reduction and Scavenging of Chemically Reactive Drug Metabolites by NAD(P)H:Quinone Oxidoreductase 1 and NRH:Quinone Oxidoreductase 2 and Variability in Hepatic Concentrations. | Chemical research in toxicology 20180219 |
| Creation and screening of a multi-family bacterial oxidoreductase library to discover novel nitroreductases that efficiently activate the bioreductive prodrugs CB1954 and PR-104A. | Biochemical pharmacology 20130415 |
| An unusually cold active nitroreductase for prodrug activations. | Bioorganic & medicinal chemistry 20120601 |
| Noninvasive optical imaging of nitroreductase gene-directed enzyme prodrug therapy system in living animals. | Gene therapy 20120301 |
| In silico screening reveals structurally diverse, nanomolar inhibitors of NQO2 that are functionally active in cells and can modulate NF-κB signaling. | Molecular cancer therapeutics 20120101 |
| The synthesis of 2-nitroaryl-1,2,3,4-tetrahydroisoquinolines, nitro-substituted 5,6-dihydrobenzimidazo[2,1-a]isoquinoline N-oxides and related heterocycles as potential bioreducible substrates for the enzymes NAD(P)H: quinone oxidoreductase 1 and E. coli nitroreductase. | Bioorganic & medicinal chemistry letters 20111215 |
| Colloidal gold modified with a genetically engineered nitroreductase: toward a novel enzyme delivery system for cancer prodrug therapy. | Langmuir : the ACS journal of surfaces and colloids 20111206 |
| Insights into the redox cycle of human quinone reductase 2. | Free radical research 20111001 |
| Co-expression of herpes simplex virus thymidine kinase and Escherichia coli nitroreductase by an hTERT-driven adenovirus vector in breast cancer cells results in additive anti-tumor effects. | Oncology reports 20110701 |
| NQO1-dependent redox cycling of idebenone: effects on cellular redox potential and energy levels. | PloS one 20110101 |
| Activation of nitrofurazone by azoreductases: multiple activities in one enzyme. | Scientific reports 20110101 |
| uvrB gene deletion enhances SOS chromotest sensitivity for nitroreductases that preferentially generate the 4-hydroxylamine metabolite of the anti-cancer prodrug CB1954. | Journal of biotechnology 20101001 |
| Quinone oxidoreductase-2-mediated prodrug cancer therapy. | Science translational medicine 20100714 |
| Transgenic mice expressing nitroreductase gene under the control of the podocin promoter: a new murine model of inductible glomerular injury. | Virchows Archiv : an international journal of pathology 20100301 |
| Bystander or no bystander for gene directed enzyme prodrug therapy. | Molecules (Basel, Switzerland) 20091110 |
| Antivector and tumor immune responses following adenovirus-directed enzyme prodrug therapy for the treatment of prostate cancer. | Human gene therapy 20091101 |
| Steady-state and stopped-flow kinetic studies of three Escherichia coli NfsB mutants with enhanced activity for the prodrug CB1954. | Biochemistry 20090818 |
| A phase I/II clinical trial in localized prostate cancer of an adenovirus expressing nitroreductase with CB1954 [correction of CB1984]. | Molecular therapy : the journal of the American Society of Gene Therapy 20090701 |
| E. coli NfsA: an alternative nitroreductase for prodrug activation gene therapy in combination with CB1954. | British journal of cancer 20090616 |
| Antitumor activity of a selectively replication competent herpes simplex virus (HSV) with enzyme prodrug therapy. | Anticancer research 20090601 |
| Mechanism of CB1954 reduction by Escherichia coli nitroreductase. | Biochemical Society transactions 20090401 |
| A new in vitro model for stem cell differentiation and interaction. | Stem cell research 20090301 |
| A mammalianized synthetic nitroreductase gene for high-level expression. | BMC cancer 20090101 |
| Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors. | Journal of medicinal chemistry 20081113 |
| The NprA nitroreductase required for 2,4-dinitrophenol reduction in Rhodobacter capsulatus is a dihydropteridine reductase. | Environmental microbiology 20081101 |
| E. coli nitroreductase/CB1954 gene-directed enzyme prodrug therapy: role of arylamine N-acetlytransferase 2. | Cancer gene therapy 20081101 |
| Optimized clostridium-directed enzyme prodrug therapy improves the antitumor activity of the novel DNA cross-linking agent PR-104. | Cancer research 20081001 |
| Gene therapy for the treatment of hip prosthesis loosening: adverse events in a phase 1 clinical study. | Human gene therapy 20081001 |
| Metabolic activation of the antitumor drug 5-(Aziridin-1-yl)-2,4-dinitrobenzamide (CB1954) by NO synthases. | Chemical research in toxicology 20080401 |
| Escherichia coli nitroreductase plus CB1954 enhances the effect of radiotherapy in vitro and in vivo. | Gene therapy 20080301 |
| SALMON: solvent accessibility, ligand binding, and mapping of ligand orientation by NMR spectroscopy. | Journal of medicinal chemistry 20080110 |
| Combining gene and immunotherapy for prostate cancer. | Prostate cancer and prostatic diseases 20080101 |
| The nitroreductase prodrug SN 28343 enhances the potency of systemically administered armed oncolytic adenovirus ONYX-411(NTR). | Cancer gene therapy 20071201 |
| Hepatic nitroreduction, toxicity and toxicokinetics of the anti-tumour prodrug CB 1954 in mouse and rat. | Toxicology 20071030 |
| Synthesis of cryptolepine analogues as potential bioreducible anticancer agents. | Bioorganic & medicinal chemistry 20071001 |
| Validation of nitroreductase, a prodrug-activating enzyme, mediated cell death in embryonic zebrafish (Danio rerio). | Comparative medicine 20070601 |
| Ablation of central nervous system progenitor cells in transgenic rats using bacterial nitroreductase system. | Journal of neuroscience research 20070501 |
| Kinetic and structural characterisation of Escherichia coli nitroreductase mutants showing improved efficacy for the prodrug substrate CB1954. | Journal of molecular biology 20070427 |
| Direct positive selection for improved nitroreductase variants using SOS triggering of bacteriophage lambda lytic cycle. | Gene therapy 20070401 |
| Synthesis and structure-activity relationships for 2,4-dinitrobenzamide-5-mustards as prodrugs for the Escherichia coli nfsB nitroreductase in gene therapy. | Journal of medicinal chemistry 20070322 |
| NAD(P)H:quinone oxidoreductase 1 and nrh:quinone oxidoreductase 2 activity and expression in bladder and ovarian cancer and lower NRH:quinone oxidoreductase 2 activity associated with an NQO2 exon 3 single-nucleotide polymorphism. | Clinical cancer research : an official journal of the American Association for Cancer Research 20070301 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20070301 |
| Repeated cycles of Clostridium-directed enzyme prodrug therapy result in sustained antitumour effects in vivo. | British journal of cancer 20061106 |
| Reduction of mitomycin C is catalysed by human recombinant NRH:quinone oxidoreductase 2 using reduced nicotinamide adenine dinucleotide as an electron donating co-factor. | British journal of cancer 20061106 |
| Application of a microfluidic reactor for screening cancer prodrug activation using silica-immobilized nitrobenzene nitroreductase. | Biomacromolecules 20060901 |
| NRH:quinone oxidoreductase 2 (NQO2) catalyzes metabolic activation of quinones and anti-tumor drugs. | Biochemical pharmacology 20060728 |
| Design, synthesis, and biological evaluation of cyclic and acyclic nitrobenzylphosphoramide mustards for E. coli nitroreductase activation. | Journal of medicinal chemistry 20060713 |
| Hypoxia: targeting the tumour. | Anti-cancer agents in medicinal chemistry 20060701 |
| Microsphere-based protease assays and screening application for lethal factor and factor Xa. | Cytometry. Part A : the journal of the International Society for Analytical Cytology 20060501 |
| Nitroreductase-based therapy of prostate cancer, enhanced by raising expression of heat shock protein 70, acts through increased anti-tumour immunity. | Cancer immunology, immunotherapy : CII 20060301 |
| Delivery of the bacterial nitroreductase gene into endothelial cells prolongs the survival of tumour-bearing mice by bystander mechanisms. | International journal of oncology 20060201 |
| New enzyme for reductive cancer chemotherapy, YieF, and its improvement by directed evolution. | Molecular cancer therapeutics 20060101 |
| Aerobic 2- and 4-nitroreduction of CB 1954 by human liver. | Toxicology 20051215 |
| Binding of the anticancer prodrug CB1954 to the activating enzyme NQO2 revealed by the crystal structure of their complex. | Journal of medicinal chemistry 20051201 |
| Late expression of nitroreductase in an oncolytic adenovirus sensitizes colon cancer cells to the prodrug CB1954. | Human gene therapy 20051201 |
| Towards gene therapy in prosthesis loosening: efficient killing of interface cells by gene-directed enzyme prodrug therapy with nitroreductase and the prodrug CB1954. | The journal of gene medicine 20051101 |
| Crystal structure of quinone reductase 2 in complex with cancer prodrug CB1954. | Biochemical and biophysical research communications 20051014 |
| Inhibition of NF-kappaB enhances the cytotoxicity of virus-directed enzyme prodrug therapy and oncolytic adenovirus cancer gene therapy. | Gene therapy 20050801 |
| Antitumor immune responses mediated by adenoviral GDEPT using nitroreductase/CB1954 is enhanced by high-level coexpression of heat shock protein 70. | Cancer gene therapy 20050601 |
| Nitroreductase: a prodrug-activating enzyme for cancer gene therapy. | Clinical and experimental pharmacology & physiology 20041101 |
| Enhanced efficacy of Escherichia coli nitroreductase/CB1954 prodrug activation gene therapy using an E1B-55K-deleted oncolytic adenovirus vector. | Gene therapy 20040701 |
| Aziridinyldinitrobenzamides: synthesis and structure-activity relationships for activation by E. coli nitroreductase. | Journal of medicinal chemistry 20040603 |
| Genes in the service of therapeutic index: progress for virus-directed enzyme prodrug therapy. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20040501 |
| 2-Amino metabolites are key mediators of CB 1954 and SN 23862 bystander effects in nitroreductase GDEPT. | British journal of cancer 20040308 |
| Enzyme-catalyzed activation of anticancer prodrugs. | Pharmacological reviews 20040301 |
| Methods to improve efficacy in suicide gene therapy approaches: targeting prodrug-activating enzymes carboxypeptidase G2 and nitroreductase to different subcellular compartments. | Methods in molecular medicine 20040101 |
| The nitroreductase/CB1954 enzyme-prodrug system. | Methods in molecular medicine 20040101 |
| Quinone reductase-mediated nitro-reduction: clinical applications. | Methods in enzymology 20040101 |
| The gene suicide system Ntr/CB1954 causes ablation of differentiated 3T3L1 adipocytes by apoptosis. | Biological research 20040101 |
| Synthesis and evaluation of nitroheterocyclic carbamate prodrugs for use with nitroreductase-mediated gene-directed enzyme prodrug therapy. | Journal of medicinal chemistry 20031204 |
| Clostridia in cancer therapy. | Nature reviews. Microbiology 20031201 |
| Bystander cell killing spreading from endothelial to tumor cells in a three-dimensional multicellular nodule model after Escherichia coli nitroreductase gene delivery. | Biochemical and biophysical research communications 20031128 |
| Nitroaryl phosphoramides as novel prodrugs for E. coli nitroreductase activation in enzyme prodrug therapy. | Journal of medicinal chemistry 20031106 |
| Studies on the nitroreductase prodrug-activating system. Crystal structures of complexes with the inhibitor dicoumarol and dinitrobenzamide prodrugs and of the enzyme active form. | Journal of medicinal chemistry 20030911 |
| Mechanism of cell death induced by the novel enzyme-prodrug combination, nitroreductase/CB1954, and identification of synergism with 5-fluorouracil. | British journal of cancer 20030901 |
| Generation of Escherichia coli nitroreductase mutants conferring improved cell sensitization to the prodrug CB1954. | Cancer research 20030901 |
| Professor Tom Connors and the development of novel cancer therapies by the Phase I/II Clinical Trials Committee of Cancer Research UK. | British journal of cancer 20030804 |
| Structure-activity relationships for 4-nitrobenzyl carbamates of 5-aminobenz[e]indoline minor groove alkylating agents as prodrugs for GDEPT in conjunction with E. coli nitroreductase. | Journal of medicinal chemistry 20030605 |
| Effect of nitroreduction on the alkylating reactivity and cytotoxicity of the 2,4-dinitrobenzamide-5-aziridine CB 1954 and the corresponding nitrogen mustard SN 23862: distinct mechanisms of bioreductive activation. | Chemical research in toxicology 20030401 |
| Immune enhancement of nitroreductase-induced cytotoxicity: studies using a bicistronic adenovirus vector. | International journal of cancer 20030310 |
| Selective ablation of human cancer cells by telomerase-specific adenoviral suicide gene therapy vectors expressing bacterial nitroreductase. | Oncogene 20030123 |
| CB 1954: from the Walker tumor to NQO2 and VDEPT. | Current pharmaceutical design 20030101 |
| Selective ablation of olfactory receptor neurons without functional impairment of vomeronasal receptor neurons in OMP-ntr transgenic mice. | The European journal of neuroscience 20021201 |
| [The trends in new drugs for the prostate cancer]. | Nihon rinsho. Japanese journal of clinical medicine 20021201 |
| Inducible ablation of adipocytes in adult transgenic mice expressing the E. coli nitroreductase gene. | The Journal of endocrinology 20021101 |
| Gene therapy trials: a patient pathway. | Nursing standard (Royal College of Nursing (Great Britain) : 1987) 20021001 |
| Current progress in suicide gene therapy for cancer. | World journal of surgery 20020701 |
| Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells. | The Journal of biological chemistry 20020419 |
| Quantitation of bystander effects in nitroreductase suicide gene therapy using three-dimensional cell cultures. | Cancer research 20020301 |
| Bacillus amyloliquefaciens orthologue of Bacillus subtilis ywrO encodes a nitroreductase enzyme which activates the prodrug CB 1954. | Microbiology (Reading, England) 20020101 |
| Inhibition of myc-dependent breast tumor formation in transgenic mice. | Breast cancer research and treatment 20020101 |
| Hypoxia-inducible regulation of a prodrug-activating enzyme for tumor-specific gene therapy. | Neoplasia (New York, N.Y.) 20020101 |
| Nitroreductase-based GDEPT. | Current pharmaceutical design 20020101 |
| British Cancer Research Meeting, 30 June-3 July 2002, Glasgow. | Breast cancer research : BCR 20020101 |
| Telomerase-specific suicide gene therapy vectors expressing bacterial nitroreductase sensitize human cancer cells to the pro-drug CB1954. | Oncogene 20011122 |
| High-level, beta-catenin/TCF-dependent transgene expression in secondary colorectal cancer tissue. | Molecular therapy : the journal of the American Society of Gene Therapy 20011001 |
| Virus-directed, enzyme prodrug therapy with nitroimidazole reductase: a phase I and pharmacokinetic study of its prodrug, CB1954. | Clinical cancer research : an official journal of the American Association for Cancer Research 20010901 |
| Appropriate subcellular localisation of prodrug-activating enzymes has important consequences for suicide gene therapy. | International journal of cancer 20010701 |
| Conditional ablation of neurones in transgenic mice. | Journal of neurobiology 20010605 |
| Inducible ablation of astrocytes shows that these cells are required for neuronal survival in the adult brain. | Glia 20010601 |
| E. coli nitroreductase/CB1954: in vitro studies into a potential system for feline cancer gene therapy. | Veterinary journal (London, England : 1997) 20010501 |
| Combined adenovirus-mediated nitroreductase gene delivery and CB1954 treatment: a well-tolerated therapy for established solid tumors. | Molecular therapy : the journal of the American Society of Gene Therapy 20010201 |
| Demonstration of the activation of prodrug CB 1954 using human DT-diaphorase mutant Q104Y-transfected MDA-MB-231 cells and mouse xenograft model. | Archives of biochemistry and biophysics 20010101 |
| Gene therapy for colorectal cancer: therapeutic potential. | BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 20010101 |